1-4 of 4
Thomas M. Caparrotta
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of COVID-19 and Non-COVID-19 Hospitalized Pneumonia on Longer-Term Cardiovascular Mortality in People With Type 2 Diabetes: A Nationwide Prospective Cohort Study From Scotland

Stuart J. McGurnaghan, Paul M. McKeigue, Luke A.K. Blackbourn, Joseph Mellor, Thomas M. Caparrotta, Naveed Sattar, Brian Kennon, David McAllister, Sarah H. Wild, Helen M. Colhoun, Scottish Diabetes Research Network Epidemiology Group
Journal: Diabetes Care
Diabetes Care 2024;47(8):1342–1349
https://doi.org/10.2337/dc24-0124
Published: 18 June 2024
View article titled, Impact of COVID-19 and Non-COVID-19 Hospitalized Pneumonia on Longer-Term Cardiovascular Mortality in People With Type 2 Diabetes: A Nationwide Prospective Cohort Study From Scotland
Open the PDF for Impact of COVID-19 and Non-COVID-19 Hospitalized Pneumonia on Longer-Term Cardiovascular Mortality in People With Type 2 Diabetes: A Nationwide Prospective Cohort Study From Scotland in another window
Journal Articles

Relation of Incident Type 1 Diabetes to Recent COVID-19 Infection: Cohort Study Using e-Health Record Linkage in Scotland

Paul M. McKeigue, Stuart McGurnaghan, Luke Blackbourn, Louise E. Bath, David A. McAllister, Thomas M. Caparrotta, Sarah H. Wild, Simon N. Wood, Diane Stockton, Helen M. Colhoun
Journal: Diabetes Care
Diabetes Care 2023;46(5):921–928
https://doi.org/10.2337/dc22-0385
Published: 26 July 2023
View article titled, Relation of Incident Type 1 Diabetes to Recent COVID-19 Infection: Cohort Study Using e-Health Record Linkage in Scotland
Open the PDF for Relation of Incident Type 1 Diabetes to Recent COVID-19 Infection: Cohort Study Using e-Health Record Linkage in Scotland in another window
Journal Articles

Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study

Joseph E. O’Reilly, Anita Jeyam, Thomas M. Caparrotta, Joseph Mellor, Andreas Hohn, Paul M. McKeigue, Stuart J. McGurnaghan, Luke A.K. Blackbourn, Rory McCrimmon, Sarah H. Wild, John R. Petrie, John A. McKnight, Brian Kennon, John Chalmers, Sam Phillip, Graham Leese, Robert S. Lindsay, Naveed Sattar, Fraser W. Gibb, Helen M. Colhoun
Journal: Diabetes Care
Diabetes Care 2021;44(9):2010–2017
https://doi.org/10.2337/dc21-0689
Published: 08 July 2021
View article titled, Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study
Open the PDF for Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study in another window
Journal Articles

Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland

Thomas M. Caparrotta, Luke A.K. Blackbourn, Stuart J. McGurnaghan, John Chalmers, Robert Lindsay, Rory McCrimmon, John McKnight, Sarah Wild, John R. Petrie, Sam Philip, Paul M. McKeigue, David J. Webb, Naveed Sattar, Helen M. Colhoun
Journal: Diabetes Care
Diabetes Care 2020;43(9):2034–2041
https://doi.org/10.2337/dc20-0120
Published: 24 June 2020
View article titled, Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland
Open the PDF for Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland in another window